Do you think patients on active surveillance would be willing to participate in a high-intensity interval exercise training program?
"My experience with patients who are on surveillance, who meet the criteria for active surveillance, [is that they] tend to be younger and healthier patients, so I don’t see why not," says one urologist.
Managing ADT-related adverse events: An expert’s view
"It’s important to recognize that there has been a shift in the way we approach ADT," says David F. Jarrard, MD.
Leuprolide tops urology spending for Medicare Part B drugs
Urologists are the principal drivers of utilization for 14 drugs.
Malpractice Consult: Affidavits of merit and why they matter
Most states require affidavits for malpractice cases to proceed.
Where can we do better in benign urology?
"Although it might be easier to enumerate the cancer conditions, in the benign world, struggles continue to overcome patients challenged with these conditions," writes Gopal H. Badlani, MD.
Can one choose a cancer diagnosis code without tissue?
Pathologic tissue confirmation is usually the best practice.
Findings support safety, feasibility of partial-gland treatment
"If adequate cancer control can be achieved by focal or partial-gland treatment, then the favorable adverse event profile could make this a preferred option for a number of men with localized intermediate-risk (and possibly selected high-risk) prostate cancer," writes Badar M. Mian, MD.
Is neuromodulation beneficial for patients with female sexual dysfunction?
A study presented at the 2022 Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU) Winter Meeting evaluated the safety and efficacy of percutaneous tibial nerve stimulation (PTNS) in patients who suffer from female sexual dysfunction.
5-year data sustain long-term effectiveness of Aquablation vs TURP in BPH
5-year results from the pivotal WATER trial showed IPSS improvement was greater with Aquablation compared with TURP.
Dr. Caleb Nelson on pediatric stone evaluation, treatment, and prevention
In this interview, Caleb Nelson, MD, PhD, discusses the current state of evaluation and treatment of stones in pediatric patients.
Neoadjuvant avelumab/axitinib shows promise in renal cell carcinoma
The combination of the PD-L1 inhibitor avelumab and the tyrosine kinase inhibitor axitinib showed promise as a neoadjuvant therapy for patients with high-risk, non-metastatic clear-cell renal cell carcinoma, according to findings from the NeoAvAx trial.
Niraparib/Cabozantinib combo shows promise in bladder and kidney cancers
The combo of the PARP inhibitor niraparib and the multikinase inhibitor cabozantinib showed positive early efficacy and safety signals in patients with metastatic urothelial carcinoma or renal cell carcinoma.
Dr. Reyblat discusses what it means to build an inclusive urology practice
In this interview, Polina X. Reyblat, MD, discusses the ways in which urologists can make their practices a more comfortable and open environment for patients of all different backgrounds to receive care.
Genetic testing and the precision medicine era of prostate cancer
In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Veda N. Giri, MD, highlights the role genetic testing has played in a new era of prostate cancer therapeutics.
2 Clarke Drive Cranbury, NJ 08512